{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:25:30Z","timestamp":1789770330654,"version":"4.0.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3397-x","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T12:35:33Z","timestamp":1538051733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Adverse effects of antiretroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study"],"prefix":"10.1186","volume":"18","author":[{"given":"Adriane M.","family":"Delicio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliane J.","family":"Lajos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabia","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Cavichiolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabeli","family":"Myioshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helaine","family":"Milanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"key":"3397_CR1","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"JD Lundgren","year":"2015","unstructured":"Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. The INSIGHT START study group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795\u2013807.","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"3397_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/cid\/civ091","volume":"60","author":"R Baggaley","year":"2015","unstructured":"Baggaley R, Doherty M, Ball A, Ford N, Gottfried HG. Department of HIV\/AIDS, World Health Organization, Geneva, Switzerland. The strategic use of antiretrovirals to prevent HIV infection: a converging agenda. Clin Infect Dis. 2015;60(Suppl 3):159\u201360.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 5","key":"3397_CR3","first-page":"506","volume":"8","author":"The Working Group on Mother-To-Child Transmission of HIV","year":"1995","unstructured":"The Working Group on Mother-To-Child Transmission of HIV. Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(Suppl 5):506\u201310.","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"3397_CR4","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1056\/NEJM199411033311801","volume":"331","author":"EM Connor","year":"1994","unstructured":"Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O\u2019Sullivan M, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173\u201380.","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"3397_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/hiv.12410","volume":"18","author":"CE French","year":"2017","unstructured":"French CE, Thorne C, Byrne L, Cortina-Borja M, Tookey PA. Presentation for care and antenatal management of HIV in the UK, 2009-2014. HIV Med. 2017;18(Suppl 3):161\u201370.","journal-title":"HIV Med"},{"key":"3397_CR6","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: WHO Guidelines Review Committee; 2013."},{"key":"3397_CR7","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Departamento de DST, Aids e Hepatites Virais. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Preven\u00e7\u00e3o da transmiss\u00e3o vertical do HIV, s\u00edfilis e hepatites virais. Bras\u00edlia. 2017."},{"issue":"Suppl 5","key":"3397_CR8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/COH.0b013e3283632b88","volume":"8","author":"ML Newell","year":"2013","unstructured":"Newell ML, Bunders MJ. Safety of antiretroviral drugs in pregnancy and breastfeeding for mother and child. Curr Opin HIV AIDS. 2013;8(Suppl 5):504\u201310.","journal-title":"Curr Opin HIV AIDS"},{"issue":"Suppl 7","key":"3397_CR9","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/infdis\/jiv389","volume":"213","author":"N Li","year":"2016","unstructured":"Li N, Sando MM, Spiegelman D, Hertzmark E, Liu E, Sando D, et al. Antiretroviral therapy in relation to birth outcomes among HIV-infected women: a cohort study. J Infect Dis. 2016;213(Suppl 7):1057\u201364.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"3397_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/QAD.0000000000000486","volume":"29","author":"C Mor\u00e9n","year":"2015","unstructured":"Mor\u00e9n C, Noguera-Juli\u00e1n A, Garrabou G, Rovira N, Catal\u00e1n M, Ba\u00f1\u00f3 M, et al. Mitochondrial disturbances in HIV pregnancies. AIDS. 2015;29(Suppl 1):5\u201312.","journal-title":"AIDS"},{"issue":"Suppl 3","key":"3397_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/QAI.0b013e31828011ca","volume":"62","author":"D Cohan","year":"2013","unstructured":"Cohan D, Mwesigwa J, Natureeba P, Aliba Luwedde F, Ades V, et al. WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity. J Acquir Immune Defic Syndr. 2013;62(Suppl 3):101\u20133.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"3397_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/QAI.0000000000000686","volume":"70","author":"JL Browne","year":"2015","unstructured":"Browne JL, Schrier VJ, Grobbee DE, Peters SA, Klipstein-Grobusch K. Antiretroviral therapy, and hypertensive disorders in pregnancy: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2015;70(Suppl 1):91\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"3397_CR13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/QAI.0000000000000811","volume":"71","author":"CJ Hoffmann","year":"2016","unstructured":"Hoffmann CJ, Cohn S, Mashabela F, Hoffmann JD, McIlleron H, Denti P, et al. Treatment failure, drug resistance, and CD4 T-cell count decline among postpartum women on antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2016;71(Suppl 1):31\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 4","key":"3397_CR14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.bjid.2013.11.008","volume":"18","author":"M Santini-Oliveira","year":"2014","unstructured":"Santini-Oliveira M, Friedman RK, Veloso VG, Cunha CB, Pilotto JH, Marins LM, et al. Incidence of antiretroviral adverse drug reactions in pregnant women in two referral centers for HIV prevention of mother-to-child-transmission care and research in Rio de Janeiro, Brazil. Braz J Infect Dis. 2014;18(Suppl 4):372\u20138.","journal-title":"Braz J Infect Dis"},{"key":"3397_CR15","volume-title":"Departamento de A\u00e7\u00f5es Program\u00e1ticas Estrat\u00e9gicas","author":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade","year":"2012","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade. Departamento de A\u00e7\u00f5es Program\u00e1ticas Estrat\u00e9gicas. Bras\u00edlia: Gesta\u00e7\u00e3o de alto risco: manual t\u00e9cnico; 2012."},{"key":"3397_CR16","unstructured":"Division of AIDS. National Institute of Allergy and Infectious Diseases. National Institutes of Health. US Department of Health and Human Services. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 2.0. Bethesda: NIH; 2014."},{"key":"3397_CR17","volume-title":"Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive","author":"WHO","year":"2011","unstructured":"WHO. Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. Geneva: UNAIDS; 2011."},{"key":"3397_CR18","volume-title":"Progress Report on the Global Plan towards the elimination of new HIV infections among children and keeping their mothers alive","author":"WHO","year":"2015","unstructured":"WHO. Progress Report on the Global Plan towards the elimination of new HIV infections among children and keeping their mothers alive. Geneva: UNAIDS; 2015."},{"key":"3397_CR19","doi-asserted-by":"crossref","unstructured":"Amaral E, Assis-Gomes F, Milanez H, Cecatti JG, Vilela MM, Pinto e Silva JL. Timely implementation of interventions to reduce vertical HIV transmission: a successful experience in Brazil, Rev Panam Salud Publica. 2007;21(Suppl 6):357\u201364.","DOI":"10.1590\/S1020-49892007000500003"},{"key":"3397_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1742-4755-8-35","volume":"8","author":"AM Delicio","year":"2011","unstructured":"Delicio AM, Milanez H, Amaral E, Morais SS, Lajos GJ, Pinto e Silva JLC, et al. Mother-to-child transmission of human immunodeficiency virus in a ten years period. Reprod Health. 2011;8:35. \n                    https:\/\/doi.org\/10.1186\/1742-4755-8-35\n                    \n                  .","journal-title":"Reprod Health"},{"issue":"Suppl 6","key":"3397_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/QCO.0000000000000017","volume":"26","author":"A Colbers","year":"2013","unstructured":"Colbers A, Greupink R, Burger D. Pharmacological considerations on the use of antiretrovirals in pregnancy. Curr Opin Infect Dis. 2013;26(Suppl 6):575\u201388.","journal-title":"Curr Opin Infect Dis"},{"issue":"Suppl 4","key":"3397_CR22","first-page":"198","volume":"13","author":"JF Senise","year":"2011","unstructured":"Senise JF, Castelo A, Mart\u00ednez M. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. AIDS Rev. 2011;13(Suppl 4):198\u2013213.","journal-title":"AIDS Rev"},{"key":"3397_CR23","first-page":"1","volume":"17","author":"M Pinho-Pompeu","year":"2016","unstructured":"Pinho-Pompeu M, Surita FG, Pastore DA, Paulino DS, Pinto E Silva JL. Anemia in pregnant adolescents: impact of treatment on perinatal outcomes. J Matern Fetal Neonatal Med. 2016;17:1\u20135.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"3397_CR24","volume-title":"Regional Office for Africa: Health Situation Analysis in the African Region","author":"WHO","year":"2011","unstructured":"WHO. Regional Office for Africa: Health Situation Analysis in the African Region. Geneva: Atlas of Health Statistics; 2011."},{"key":"3397_CR25","unstructured":"Saving Mothers 2008\u20132010. Fifth Report on Confidential Enquiries into Maternal Deaths in South Africa. Comprehensive Report. Compiled by the National Committee for Confidential Enquiry into Maternal Deaths. Department Health Republic of South Africa. South Africa. 2012. \n                    http:\/\/sanac.org.za\/wp-content\/uploads\/2015\/12\/Report_on_Confidential_Enquiries_into_Maternal_Deaths_in_South_Africa.pdf\n                    \n                  ."},{"key":"3397_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/jama.1994.03520060037029","volume":"272","author":"PA Volberding","year":"1994","unstructured":"Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA. 1994;272:437\u201342.","journal-title":"JAMA"},{"key":"3397_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1185\/030079906X162683","volume":"23","author":"D Mildvan","year":"2007","unstructured":"Mildvan D, Creagh T, Leitz G, Group APS. Prevalence of anemia and correlation with biomarkers and specific antiretroviralregimens in 9690 human-immunodeficiency-virus-infectedpatients: findings of the Anemia prevalence study. Curr Med Res Opin. 2007;23:343\u201355.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 3","key":"3397_CR28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/2325957413502543","volume":"14","author":"AD Iuliano","year":"2015","unstructured":"Iuliano AD, Weidle PJ, Brooks JT, Masaba R, Girde S, Ndivo R, et al. Neutropenia in HIV-infected Kenyan women receiving triple antiretroviral prophylaxis to prevent mother-to-child HIV transmission is not associated with serious clinical sequelae. J Int Assoc Provid AIDS Care. 2015;14(Suppl 3):261\u20138.","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"3397_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/00002030-199818000-00002","volume":"12","author":"P Lorenzi","year":"1998","unstructured":"Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS. 1998;12:241\u20137.","journal-title":"AIDS"},{"key":"3397_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/01.qai.0000139398.38236.4d","volume":"38","author":"RE Tuomala","year":"2005","unstructured":"Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, Landesman S, Zorrilla C, Thompson B. Women and Infants Transmission Study. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antirretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005;38:449\u201373.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 3","key":"3397_CR31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/tmi.12662","volume":"21","author":"C Odhiambo","year":"2016","unstructured":"Odhiambo C, Zeh C, Angira F, Opollo V, Akinyi B, Masaba R, et al. Anaemia in HIV-infected pregnant women receiving triple antiretroviral combination therapy for prevention of mother-to-child transmission: a secondary analysis of the Kisumu breastfeeding study (KiBS). Tropical Med Int Health. 2016;21(Suppl 3):373\u201384.","journal-title":"Tropical Med Int Health"},{"key":"3397_CR32","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1186\/1471-2334-13-52","volume":"13","author":"KD Benn","year":"2013","unstructured":"Benn KD, Chersich MF, Mary M, Nicolas M, Marleen T, et al. Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three African countries. BMC Infect Dis. 2013;13:522. \n                    https:\/\/doi.org\/10.1186\/1471-2334-13-52\n                    \n                  .","journal-title":"BMC Infect Dis"},{"issue":"Suppl 9","key":"3397_CR33","doi-asserted-by":"publisher","first-page":"e106103","DOI":"10.1371\/journal.pone.0106103","volume":"9","author":"V Nandlal","year":"2014","unstructured":"Nandlal V, Moodley D, Grobler A, Bagratee J, Maharaj NR, Richardson P. Anaemia in pregnancy is associated with advanced HIV disease. PLoS One. 2014;9(Suppl 9):e106103. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0106103\n                    \n                  .","journal-title":"PLoS One"},{"issue":"Suppl 18","key":"3397_CR34","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1511691","volume":"375","author":"MG Fowler","year":"2016","unstructured":"Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. IMPAACT 1077BF\/1077FF PROMISE Study Team. N Engl J Med. 2016;375(Suppl 18):1726\u201337.","journal-title":"N Engl J Med"},{"key":"3397_CR35","doi-asserted-by":"publisher","first-page":"867674","DOI":"10.1155\/2011\/867674","volume":"2011","author":"A Weinberg","year":"2011","unstructured":"Weinberg A, Forster-Harwood J, Davies J, McFarland EJ, Pappas J, Kinzie K, et al. Safety and tolerability of antiretrovirals during pregnancy. Infect Dis Obstet Gynecol. 2011;2011:867674. \n                    https:\/\/doi.org\/10.1155\/2011\/867674\n                    \n                  .","journal-title":"Infect Dis Obstet Gynecol"},{"issue":"Suppl 2","key":"3397_CR36","first-page":"132","volume":"14","author":"LO Coster","year":"2012","unstructured":"Coster LO, Kumar PN. Contemporary role of Nevirapine in HIV treatment. AIDS Rev. 2012;14(Suppl 2):132\u201344.","journal-title":"AIDS Rev"},{"issue":"Suppl 3","key":"3397_CR37","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1097\/QAI.0b013e31828011ca","volume":"62","author":"D Cohan","year":"2013","unstructured":"Cohan D, Mwesigwa J, Natureeba P, Aliba Luwedde F, Ades V, et al. WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity. J Acquir Immune Defic Syndr. 2013;62(Suppl 3):e101\u20133. \n                    https:\/\/doi.org\/10.1097\/QAI.0b013e31828011ca\n                    \n                  .","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3397_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ajog.2005.05.015","volume":"194","author":"ES Jo\u00e3o","year":"2006","unstructured":"Jo\u00e3o ES, Calvet GA, Menezes JA, D\u2019ippolito MM, Cruz MLS, Salgado LAT, et al. Nevirapine toxicity in a cohort of HIV-1\u2013infected pregnant women. Am J Obstet Gynecol. 2006;194:199\u2013202.","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 4","key":"3397_CR39","first-page":"409","volume":"64","author":"IJ Snijdewind","year":"2012","unstructured":"Snijdewind IJ, Smit C, Godfried MH, Nellen JF, de Wolf F, Boer K, et al. HCV coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy. J Inf Secur. 2012;64(Suppl 4):409\u201316.","journal-title":"J Inf Secur"},{"key":"3397_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-180","volume":"14","author":"M Andreotti","year":"2014","unstructured":"Andreotti M, Pirillo MF, Liotta G, Jere H, Maulidi M, Sagno JB, et al. The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi. BMC Infect Dis. 2014;14:180. \n                    https:\/\/doi.org\/10.1186\/1471-2334-14-180\n                    \n                  .","journal-title":"BMC Infect Dis"},{"issue":"Suppl 2","key":"3397_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/QAD.0000000000000531","volume":"29","author":"D Cohan","year":"2015","unstructured":"Cohan D, Natureeba P, Koss CA, Plenty A, Luwedde F, Mwesigwa J, et al. Efficacy and safety of lopinavir\/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. AIDS. 2015;29(Suppl 2):183\u201391.","journal-title":"AIDS"},{"key":"3397_CR42","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1097\/QAD.0000000000000231","volume":"28","author":"Nathan Ford","year":"2014","unstructured":"Ford N, Mofenson L, Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, et al. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2014; 28 Suppl 2:S123\u20133.","journal-title":"AIDS"},{"key":"3397_CR43","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Departamento de DST, Aids e Hepatites Virais. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Preven\u00e7\u00e3o da transmiss\u00e3o vertical do HIV, s\u00edfilis e hepatites virais. Bras\u00edlia. 2015."},{"key":"3397_CR44","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s10461-011-9939-5","volume":"15","author":"CA Kenedi","year":"2011","unstructured":"Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. 2011;15:1803\u201318.","journal-title":"AIDS Behav"},{"issue":"4 Suppl 3","key":"3397_CR45","doi-asserted-by":"publisher","first-page":"19512","DOI":"10.7448\/IAS.17.4.19512","volume":"17","author":"C Smith","year":"2014","unstructured":"Smith C, Ryom L, Monforte AD, Reiss P, Mocroft A, El-Sadr W, et al. Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. J Int AIDS Soc. 2014;17(4 Suppl 3):19512. \n                    https:\/\/doi.org\/10.7448\/IAS.17.4.19512\n                    \n                  .","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"3397_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","volume":"63","author":"JK Rockstroh","year":"2013","unstructured":"Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P, STARTMRK Investigators. Durable efficacy and safety of raltegravir versus efavirenz when combined with Tenofovir\/Emtricitabine in treatment-naive HIV-1\u2013infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63(1):77\u201385. \n                    https:\/\/doi.org\/10.1097\/QAI.0b013e31828ace69\n                    \n                  .","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 5","key":"3397_CR47","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/00126334-200108150-00004","volume":"27","author":"B Rakotoambinina","year":"2001","unstructured":"Rakotoambinina B, M\u00e9dioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr. 2001;27(Suppl 5):443\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 3","key":"3397_CR48","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/00126334-200303010-00009","volume":"32","author":"JE Justman","year":"2003","unstructured":"Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32(Suppl 3):298\u2013302.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 2","key":"3397_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/2325957415601503","volume":"15","author":"O Guira","year":"2016","unstructured":"Guira O, Ti\u00e9no H, Diend\u00e9r\u00e9 AE, Sagna Y, Diallo I, Yam\u00e9ogo B, et al. Features of metabolic syndrome and its associated factors during highly active antiretroviral therapy in Ouagadougou (Burkina Faso). J Int Assoc Provid AIDS Care. 2016;15(Suppl 2):159\u201363.","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"Suppl 3","key":"3397_CR50","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40265-013-0017-3","volume":"73","author":"N Andany","year":"2013","unstructured":"Andany N, Loutfy MR. HIV protease inhibitors in pregnancy: pharmacology and clinical use. Drugs. 2013;73(Suppl 3):229\u201347.","journal-title":"Drugs"},{"key":"3397_CR51","first-page":"253","volume":"5","author":"I Chougrani","year":"2013","unstructured":"Chougrani I, Luton D, Matheron S, Mandelbrot L, Azria E. Safety of protease inhibitors in HIV-infected pregnant women. HIV\/ AIDS Res Palliative Care. 2013;5:253\u201362.","journal-title":"HIV\/ AIDS Res Palliative Care"},{"issue":"Suppl 1","key":"3397_CR52","first-page":"14","volume":"16","author":"G Guaraldi","year":"2014","unstructured":"Guaraldi G, Stentarelli C, Da Silva AD, Luzi K, Neri I, Cellini M, et al. Metabolic alterations in HIV-infected pregnant women: moving to metabolic tailoring of antiretroviral drugs. AIDS Rev. 2014;16(Suppl 1):14\u201322.","journal-title":"AIDS Rev"},{"issue":"Suppl 1","key":"3397_CR53","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.biochi.2004.12.007","volume":"87","author":"C Lagathu","year":"2005","unstructured":"Lagathu C, Kim M, Maachi M, Vigouroux C, Cervera P, Capeau J, et al. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochimie. 2005;87(Suppl 1):65\u201371.","journal-title":"Biochimie"},{"issue":"Suppl 2","key":"3397_CR54","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ajog.2003.07.018","volume":"190","author":"H Watts","year":"2004","unstructured":"Watts H, Balasubramanian R, Maupin RT Jr, Delke I, Dorenbaum A, Fiore S, et al. PACTG 316 Study Team. Maternal toxicity and pregnancy complications in human immunodeficiency viruseinfected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol. 2004;190(Suppl 2):506\u201316.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"3397_CR55","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12978-018-0513-8","volume":"15","author":"AM Delicio","year":"2018","unstructured":"Delicio AM, Lajos GJ, Amaral E, Cavichiolli F, Polydoro M, Milanez H. Adverse effects in children exposed to maternal HIV and antiretroviral therapy during pregnancy in Brazil: a cohort study. Reprod Health. 2018;15(1):76. \n                    https:\/\/doi.org\/10.1186\/s12978-018-0513-8\n                    \n                  .","journal-title":"Reprod Health"},{"key":"3397_CR56","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1086\/427287","volume":"40","author":"The European Collaborative Study","year":"2005","unstructured":"The European Collaborative Study. Mother to child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:458\u201365.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3397-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3397-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3397-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T23:28:07Z","timestamp":1569540487000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3397-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3397"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3397-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,27]]},"assertion":[{"value":"1 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research project was approved by the research committee at the Department of Gynecology and Obstetrics CAISM\/UNICAMP and by the University of Campinas School of Medical Sciences ethics review board (Project number 351\/2006) and since it is a retrospective study, it was exempt from an informed consent form.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"485"}}